RU2019133787A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019133787A3 RU2019133787A3 RU2019133787A RU2019133787A RU2019133787A3 RU 2019133787 A3 RU2019133787 A3 RU 2019133787A3 RU 2019133787 A RU2019133787 A RU 2019133787A RU 2019133787 A RU2019133787 A RU 2019133787A RU 2019133787 A3 RU2019133787 A3 RU 2019133787A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163837.2 | 2017-03-30 | ||
EP17163837 | 2017-03-30 | ||
EP17204926 | 2017-12-01 | ||
EP17204926.4 | 2017-12-01 | ||
PCT/EP2018/057708 WO2018178040A1 (en) | 2017-03-30 | 2018-03-27 | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019133787A RU2019133787A (ru) | 2021-04-30 |
RU2019133787A3 true RU2019133787A3 (ru) | 2021-08-10 |
RU2765997C2 RU2765997C2 (ru) | 2022-02-07 |
Family
ID=61899231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019133787A RU2765997C2 (ru) | 2017-03-30 | 2018-03-27 | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |
Country Status (13)
Country | Link |
---|---|
US (2) | US20200048352A1 (ru) |
EP (1) | EP3600410A1 (ru) |
JP (1) | JP7166278B2 (ru) |
KR (1) | KR102644408B1 (ru) |
CN (1) | CN110494161A (ru) |
AU (1) | AU2018241774A1 (ru) |
BR (1) | BR112019019939A2 (ru) |
CA (1) | CA3058276A1 (ru) |
IL (1) | IL269718A (ru) |
MX (1) | MX2019011657A (ru) |
RU (1) | RU2765997C2 (ru) |
SG (2) | SG11201909064RA (ru) |
WO (1) | WO2018178040A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107405401B (zh) * | 2015-02-26 | 2022-02-01 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
EP3310810A1 (en) | 2015-06-16 | 2018-04-25 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
EP3522923A1 (en) | 2016-10-06 | 2019-08-14 | Pfizer Inc | Dosing regimen of avelumab for the treatment of cancer |
BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
CN113365659B (zh) * | 2019-01-31 | 2023-08-18 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
WO2020259613A1 (zh) * | 2019-06-27 | 2020-12-30 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的喹啉和噌啉衍生物 |
WO2023019308A1 (en) * | 2021-08-17 | 2023-02-23 | Telix International Pty Ltd | Combination radiotherapy |
WO2023232100A1 (zh) * | 2022-06-02 | 2023-12-07 | 正大天晴药业集团股份有限公司 | 用于治疗子宫恶性肿瘤的药物组合 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12467A (en) | 1855-02-27 | And jas | ||
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
UA109108C2 (ru) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитело к pd-l1 и его применение для усиления функции t-клеток |
ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
MX2013002084A (es) | 2010-08-31 | 2013-05-09 | Genentech Inc | Biomarcadores y metodos de tratamiento. |
CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
CN113549159A (zh) * | 2014-02-10 | 2021-10-26 | 默克专利有限公司 | 靶向TGFβ抑制 |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
WO2016077505A2 (en) * | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
CN107405401B (zh) * | 2015-02-26 | 2022-02-01 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
EP3268037B1 (en) * | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
EP3310810A1 (en) | 2015-06-16 | 2018-04-25 | Merck Patent GmbH | Pd-l1 antagonist combination treatments |
-
2018
- 2018-03-27 EP EP18715582.5A patent/EP3600410A1/en active Pending
- 2018-03-27 CN CN201880023388.3A patent/CN110494161A/zh active Pending
- 2018-03-27 JP JP2019553550A patent/JP7166278B2/ja active Active
- 2018-03-27 SG SG11201909064R patent/SG11201909064RA/en unknown
- 2018-03-27 AU AU2018241774A patent/AU2018241774A1/en active Pending
- 2018-03-27 CA CA3058276A patent/CA3058276A1/en active Pending
- 2018-03-27 US US16/498,171 patent/US20200048352A1/en not_active Abandoned
- 2018-03-27 BR BR112019019939A patent/BR112019019939A2/pt unknown
- 2018-03-27 SG SG10202110707UA patent/SG10202110707UA/en unknown
- 2018-03-27 MX MX2019011657A patent/MX2019011657A/es unknown
- 2018-03-27 KR KR1020197031936A patent/KR102644408B1/ko active IP Right Grant
- 2018-03-27 RU RU2019133787A patent/RU2765997C2/ru active
- 2018-03-27 WO PCT/EP2018/057708 patent/WO2018178040A1/en unknown
-
2019
- 2019-09-26 IL IL26971819A patent/IL269718A/en unknown
-
2022
- 2022-12-23 US US18/146,014 patent/US20230272083A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2019133787A (ru) | 2021-04-30 |
SG11201909064RA (en) | 2019-10-30 |
CA3058276A1 (en) | 2018-10-04 |
KR102644408B1 (ko) | 2024-03-07 |
AU2018241774A1 (en) | 2019-11-14 |
CN110494161A (zh) | 2019-11-22 |
BR112019019939A2 (pt) | 2020-04-28 |
SG10202110707UA (en) | 2021-11-29 |
WO2018178040A1 (en) | 2018-10-04 |
RU2765997C2 (ru) | 2022-02-07 |
US20200048352A1 (en) | 2020-02-13 |
EP3600410A1 (en) | 2020-02-05 |
IL269718A (en) | 2019-11-28 |
JP7166278B2 (ja) | 2022-11-07 |
JP2020515609A (ja) | 2020-05-28 |
KR20190135028A (ko) | 2019-12-05 |
US20230272083A1 (en) | 2023-08-31 |
MX2019011657A (es) | 2019-11-18 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Changing information about inventors |